Targeted cargo protein combination therapy

Abstract

The present invention combines a targeted cargo protein with an active agent for the treatment of a disease or condition.

1 . A method of treating a disease or condition in a subject comprising administering to the subject a targeted cargo protein in combination with an active agent, wherein said targeted cargo protein comprises a first portion that is specific for a target cell surface molecule associated with the disease or condition and a second portion that inhibits said cell, and wherein said active agent comprises any therapeutically appropriate substance for treating the disease or condition. 
     
     
         2 . The method of  claim 1 , wherein the target cell surface molecule is an IL-4 receptor. 
     
     
         3 . The method of  claim 1 , wherein the targeted cargo protein is selected from at least one of the group consisting of PRX321, IL4-BAD, DT-IL-4, and IL-4 doxorubicin. 
     
     
         4 . The method of  claim 1 , wherein the active agent is a chemotherapeutic agent. 
     
     
         5 . The method of  claim 4 , wherein said chemotherapeutic agent is an active agent selected from the group consisting of gemcitabine, cisplatin, FOLFOX (folinic acid, fluorouracil and oxaliplatin) and doxorubicin. 
     
     
         6 . The method of  claim 1 , wherein said disease is cancer. 
     
     
         7 . The method of  claim 1 , wherein said disease is a cancer that over-expresses IL-4 receptors. 
     
     
         8 . The method of  claim 1 , wherein said disease is selected from the group consisting of brain cancer, malignant astrocytoma, gliobastoma multiforme, Kaposi sarcoma, bladder cancer, renal cell cancer, breast cancer, pancreatic cancer, non-small cell lung cancer, thyroid cancer, squamous cell carcinoma of the head and neck, colon cancer, gastrointestinal system, mesothelioma and prostate cancer. 
     
     
         9 . The method of  claim 8 , wherein said disease is pancreatic cancer. 
     
     
         10 . The method of  claim 9 , wherein said pancreatic cancer is pancreatic ductal adenocarcinoma (PDA). 
     
     
         11 . The method of  claim 1 , wherein the targeted cargo protein is administered concurrently with the active agent. 
     
     
         12 . A method of treating pancreatic cancer in a subject comprising administering to the subject a composition comprising PRX321 and a composition comprising gemcitabine. 
     
     
         13 . A method of inhibiting a target cell that is characterized by over-expression of an IL-4 receptor, comprising
 a. contacting the target cell with a targeted cargo protein, said targeted cargo protein comprising a targeting moiety that specifically binds to an IL-4 receptor and a cargo moiety that inhibits the target cell, and   b. contacting the target cells with an active agent.   
     
     
         14 . The method of  claim 13 , wherein the target cell is contacted with the targeted cargo protein concurrently with, or within 24 hours, within 48 hours, within 72 hours or within 96 hours of contacting the target cell with the active agent. 
     
     
         15 . The method of  claim 13 , wherein the targeted cargo protein is selected from the group consisting of PRX321, IL4-BAD, DT-IL-4, and IL-4 doxorubicin 
     
     
         16 . The method of  claim 13 , wherein the target cell is a cancer cell. 
     
     
         17 . The method of  claim 13 , wherein the target cell is selected from the group consisting of brain cancer cell, malignant astrocytoma cell, gliobastoma multiforme cell, Kaposi sarcoma cell, bladder cancer cell, renal cancer cell, breast cancer cell, pancreatic cancer cell, lung cancer cell, thyroid cancer cell, squamous cell carcinoma cell of the head and neck, colon cancer cell gastrointestinal cancer cell, mesothelioma cell and prostate cancer cell. 
     
     
         18 . The method of  claim 16 , wherein the cancer cell is pancreatic cancer cells. 
     
     
         19 . The method of  claim 13 , wherein the targeted cargo protein is PRX321. 
     
     
         20 . The method of  claim 13 , wherein the active agent is selected from the group consisting of gemcitabine, doxorubicin, FOLFOX (folinic acid, fluorouracil and oxaliplatin) and cisplatin.